Prime Medicine PRME Accretion (Amortization) of Discounts and Premiums, Short-Term Investments
Accretion (Amortization) of Discounts and Premiums, Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept prme:AccretionAmortizationOfDiscountsAndPremiumsShortTermInvestments.
The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prime Medicine's accretion (amortization) of discounts and premiums, short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prime Medicine's accretion (amortization) of discounts and premiums, short-term investments?
- Prime Medicine (PRME) reported accretion (amortization) of discounts and premiums, short-term investments of $431K in Q1 2026.
- How has Prime Medicine's accretion (amortization) of discounts and premiums, short-term investments changed year-over-year?
- Prime Medicine's accretion (amortization) of discounts and premiums, short-term investments increased by 162.8% year-over-year, from $164K to $431K.
- What does accretion (amortization) of discounts and premiums, short-term investments mean?
- This represents the non-cash adjustment to net income resulting from the amortization of premiums or the accretion of discounts on short-term investment securities. It reflects the systematic recognition of interest income over the life of the investment, adjusting the carrying value of the securities to their par value at maturity. This metric is essential for reconciling net income to cash flow from operations by removing non-cash interest components.